CytoLumina is dedicated to expanding precision medicine through the development of nanotechnology-enabled rare-cell capture and sorting platforms.
Market:CytoLumina Technologies Corp. is a leader in using circulating tumor cells (CTC) to enable personalized cancer care. The separation and analysis of CTCs from patient blood samples provide a means of understanding tumors across disease sites, including the primary tumor and metastases. The global market for CTC based cancer diagnostics and CTC monitoring is expected to reach $8.9 billion by 2018.
Technology:CytoLumina established the unique concept of CytoTrapNano™ cell-affinity substrates in which nanostructured substrates are coated with a cell capture agent that targets a specific type of cancer cell. When coupled with a microfluidic chaotic mixer, the system is able to isolate CTCs from a patient blood sample with high efficiency and accuracy.
- Transformative access to inaccessible tumors
- Safe, eliminates traditional tissue biopsies
- Accurate detection of CTCs
- Low cost option for cancer monitoring
- Device for capturing circulating cells; 9,140,697 on 3/18/2010
- Systems, Methods and Components for Isolating Cells from a Fluid Sample; PCT/US2013/043171 on 5/29/2013
- Selective capture and stimulated release of circulating cells on nanostructured devices; PCT/US2013/053063 on July 31, 2013
- UCLA scientists use ‘NanoVelcro’ and temperature control to extract tumor cells from blood | UCLA Newsroom
- Cedars-Sinai, UCLA Scientists Use New 'Blood Biopsies' With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread | Cedars-Sinai Newsroom
- Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells | Theranostics
- Highly Efficient Capture of Circulating Tumor Cells Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers | Angew Chem Int Ed Engl.
YouTube: Mechanism of NanVelcro CTC Assay